MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $246.31 million. The enterprise value is $129.54 million.
| Market Cap | 246.31M |
| Enterprise Value | 129.54M |
Important Dates
The last earnings date was Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 63.56 million shares outstanding. The number of shares has increased by 0.77% in one year.
| Current Share Class | 63.56M |
| Shares Outstanding | 63.56M |
| Shares Change (YoY) | +0.77% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 2.63% |
| Owned by Institutions (%) | 55.21% |
| Float | 52.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.57 |
| Forward PS | 2.06 |
| PB Ratio | 12.38 |
| P/TBV Ratio | 11.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.90, with a Debt / Equity ratio of 1.72.
| Current Ratio | 1.90 |
| Quick Ratio | 1.72 |
| Debt / Equity | 1.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.78 |
Financial Efficiency
Return on equity (ROE) is -140.27% and return on invested capital (ROIC) is -45.65%.
| Return on Equity (ROE) | -140.27% |
| Return on Assets (ROA) | -17.98% |
| Return on Invested Capital (ROIC) | -45.65% |
| Return on Capital Employed (ROCE) | -52.21% |
| Weighted Average Cost of Capital (WACC) | 13.17% |
| Revenue Per Employee | $536,119 |
| Profits Per Employee | -$240,130 |
| Employee Count | 293 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 19.30 |
Taxes
| Income Tax | -672,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +154.93% in the last 52 weeks. The beta is 1.20, so MacroGenics's price volatility has been higher than the market average.
| Beta (5Y) | 1.20 |
| 52-Week Price Change | +154.93% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 2.31 |
| Relative Strength Index (RSI) | 48.73 |
| Average Volume (20 Days) | 705,919 |
Short Selling Information
The latest short interest is 4.98 million, so 7.83% of the outstanding shares have been sold short.
| Short Interest | 4.98M |
| Short Previous Month | 4.88M |
| Short % of Shares Out | 7.83% |
| Short % of Float | 9.49% |
| Short Ratio (days to cover) | 3.46 |
Income Statement
In the last 12 months, MacroGenics had revenue of $157.08 million and -$70.36 million in losses. Loss per share was -$1.11.
| Revenue | 157.08M |
| Gross Profit | -25.50M |
| Operating Income | -63.66M |
| Pretax Income | -71.03M |
| Net Income | -70.36M |
| EBITDA | -56.57M |
| EBIT | -63.66M |
| Loss Per Share | -$1.11 |
Balance Sheet
The company has $154.23 million in cash and $36.51 million in debt, with a net cash position of $117.72 million or $1.85 per share.
| Cash & Cash Equivalents | 154.23M |
| Total Debt | 36.51M |
| Net Cash | 117.72M |
| Net Cash Per Share | $1.85 |
| Equity (Book Value) | 21.20M |
| Book Value Per Share | 0.33 |
| Working Capital | 86.58M |
Cash Flow
In the last 12 months, operating cash flow was -$69.96 million and capital expenditures -$1.73 million, giving a free cash flow of -$71.69 million.
| Operating Cash Flow | -69.96M |
| Capital Expenditures | -1.73M |
| Depreciation & Amortization | 7.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -71.69M |
| FCF Per Share | -$1.13 |
Margins
Gross margin is -16.24%, with operating and profit margins of -40.52% and -44.79%.
| Gross Margin | -16.24% |
| Operating Margin | -40.52% |
| Pretax Margin | -45.22% |
| Profit Margin | -44.79% |
| EBITDA Margin | -36.01% |
| EBIT Margin | -40.52% |
| FCF Margin | n/a |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.77% |
| Shareholder Yield | -0.77% |
| Earnings Yield | -28.46% |
| FCF Yield | -28.99% |
Analyst Forecast
The average price target for MacroGenics is $6.75, which is 74.19% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.75 |
| Price Target Difference | 74.19% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | -3.35% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -7.67 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.67 |
| Piotroski F-Score | 3 |